Advances in the interventional therapy of primary liver cancer combined with hepatic artery-portal vein shunts

doi:10.3877/cma.j.issn.2095-5782.2022.02.015

Abstract

Abstract:

Hepatocellular carcinoma complicated with arterial-portal shunts is not uncommon in clinical practice, which seriously restricts and affects the implementation and outcome of interventional treatment. With the development of interventional devices, vascular superselection techniques, embolic materials and immune and targeted drugs for hepatocellular carcinoma in recent years, the prognosis of patients with hepatocellular carcinoma combined with arterial-portal shunts has improved significantly. The purpose of this article is to summarize the progress of interventional treatment for hepatocellular carcinoma with arterial-portal shunts and to discuss the current challenges in interventional treatment.

Key words: Hepatocellular carcinoma, Transarlerial chemoembolization, Arterio-portal shunt, Interventional therapy

Pan Jiao, Jia Qin, Xuying Chen, Chao Li, Xiaolin Zhang. Advances in the interventional therapy of primary liver cancer combined with hepatic artery-portal vein shunts[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(02): 209-214.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2022.02.015

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2022/V10/I02/209

References 57

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3): 209-249.
[2]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[3]	Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35(9): 2155-2166.
[4]	孙磊, 施海彬, 刘圣,等. 肝细胞癌肝动脉门静脉分流形成的相关因素分析[J]. 介入放射学杂志, 2012, 21(3): 206-210.
[5]	Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment[J]. Curr Probl Diagn Radiol, 2015, 44(6): 479-486.
[6]	Jagannath S,Shalimar.Advances in management of hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2016, 6(1): 68-70.
[7]	李万湖, 董帅, 胡旭东, 等. 多层螺旋CT血管造影对原发性肝癌动静脉瘘和肝外供血动脉评估价值[J]. 中华肿瘤防治杂志, 2017, 24(11): 755-758.
[8]	Heaston DK, Chuang VP, Wallace S, et al. Metastatic hepatic neoplasms: angiographic features of portal vein involvement[J].AJR Am J Roentgenol, 1981, 136(5): 897-900.
[9]	Fares N, Péron JM.Epidemiology, natural history, and risk factors of hepatocellular carcinoma[J]. Rev Prat, 2013, 63(2): 216-217, 220-222.
[10]	Chen X, Liu L, Pan X. Portal vein tumor thrombus in advanced hepatocellular carcinoma: a case report[J]. Oncol Lett, 2015, 9(6): 2495-2498.
[11]	林福煌, 吴宁, 李斯锐, 等. 原发性肝癌合并门静脉瘘TACE药代动力学影响因素的研究[J]. 实用癌症杂志, 2017, 32(10): 1674-1676, 1684.
[12]	Okuyama M, Fujiwara Y, Hayakawa T, et al. Esophagogastric varices due to arterioportal shunt in a serous cystadenoma of the pancreas in von Hippel-Lindau disease[J]. Dig Dis Sci, 2003, 48(10): 1948-1954.
[13]	中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]. 中华肝脏病杂志, 2019, 27(3): 172-181.
[14]	Shi HB, Yang ZQ, Liu S, et al. Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2013, 36(2): 412-421.
[15]	Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370.
[16]	Pua U. High-flow arterio-hepatic venous shunt in hepatocellular carcinoma: use of multi-electrode radiofrequency for shunt obliteration[J]. Cardiovasc Intervent Radiol, 2015, 38(5): 1330-1334.
[17]	Sacco R, Tapete G, Simonetti N, et al. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review[J]. J Hepatocell Carcinoma, 2017, 4: 105-110.
[18]	Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial[J]. Cancer Biol Ther, 2017, 18(6): 433-438.
[19]	Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1): 106-116.
[20]	Chan WS, Poon WL, Cho DH, et al. Transcatheter embolisation of intrahepatic arteriovenous shunts in patients with hepatocellular carcinoma[J]. Hong Kong Med J, 2010, 16(1): 48-55.
[21]	Xu HF, Yang RJ, Chen H, et al. Interventional therapy of hepatic artery-portal vein fistula with gelatin sponge and lipiodol[J].Zhonghua Yi Xue Za Zhi, 2011, 91(15): 1061-1063.
[22]	肖景坤, 吕维富, 周春泽, 等. 原发性肝癌伴动静脉瘘介入栓塞治疗62例回顾性分析[J]. 介入放射学杂志, 2014, 23(8): 683-687.
[23]	薛兴存, 武学伟. 阿霉素海藻酸钠微球联合碘化油肝动脉栓塞治疗肝癌合并动静脉分流效果观察[J]. 实用肝脏病杂志, 2017, 20(2): 246-247.
[24]	王福安, 眭未凡, 吕朋华, 等. 海藻酸钠微球联合肝动脉化疗栓塞治疗原发性肝癌的Meta分析[J]. 中华介入放射学电子杂志, 2016, 4(4): 192-196.
[25]	Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design[J]. J Hepatol, 2012, 56(6): 1330-1335.
[26]	郝明志, 林海澜, 余文昌, 等. 经肝动脉导管注射无水乙醇碘化油乳剂治疗肝癌动静脉瘘[J]. 中国介入影像与治疗学, 2006, 3(6): 432-435.
[27]	Li J, Kang X, Guo L, et al. Embolization of hepatic arterioportal shunt with ethanol-soaked gelatin sponge[J]. J Cancer Res Ther, 2019, 15(2): 336-340.
[28]	周卫忠, 刘圣, 杨正强, 等. 氰基丙烯酸酯胶栓塞原发性肝细胞癌合并重度肝动脉门静脉瘘12例疗效分析[J]. 介入放射学杂志, 2013, 22(8): 641-645.
[29]	宿贝贝, 董景辉, 王华明, 等. 肝脏原发性淋巴瘤1例报告[J].山东医药, 2015(40): 106-106.
[30]	Lyu N, Lin Y, Kong Y, et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J].Gut, 2018, 67(2): 395-396.
[31]	Akpek S,Ilgit ET,Cekirge S, et al.High-flow arterioportal fistula: treatment with detachable balloon occlusion[J].Abdom Imaging,2001,26(3):277-280.
[32]	Koc O, Cil BE, Peynircioglu B, et al. Complementary use of NBCA with the Amplatzer vascular plug for embolization of a high-flow traumatic hepatic arteriovenous fistula[J]. Cardiovasc Intervent Radiol, 2009, 32(5): 1105-1107.
[33]	Takao H, Shibata E, Ohtomo K. Double-balloon-assisted n-butyl-2-cyanoacrylate embolization of intrahepatic arterioportal shunt prior to chemoembolization of hepatocellular carcinoma[J].Cardiovasc Intervent Radiol, 2016, 39(10): 1479-1483.
[34]	Luo W, Zhang Y, He G, et al. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis[J]. World J Surg Oncol, 2017, 15(1): 126.
[35]	Chinnaratha MA, Chuang MY, Fraser RJ, et al. Percutaneous thermal ablation for primary hepatocellular carcinoma: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2016, 31(2): 294-301.
[36]	Orlacchio A, Bolacchi F, Chegai F, et al. Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm[J]. Radiol Med, 2014, 119(5): 298-308.
[37]	Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma[J]. Hepatology, 2015, 61(5): 1579-1590.
[38]	Yang B, Zan RY, Wang SY, et al. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials[J]. World J Surg Oncol, 2015, 13: 96.
[39]	Sonomura T, Kawai N, Kishi K, et al. N-butyl cyanoacrylate embolization with blood flow control of an arterioportal shunt that developed after radiofrequency ablation of hepatocellular carcinoma[J]. Korean J Radiol, 2014, 15(2): 250-253.
[40]	Kallini JR, Gabr A, Salem R, et al. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma[J].Adv Ther, 2016, 33(5): 699-714.
[41]	Gordon AC, Gabr A, Riaz A, et al. Radioembolization super survivors: extended survival in non-operative hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2018, 41(10): 1557-1565.
[42]	王舒婷, 陈海波, 施昌盛, 等. 经皮射频消融联合¹²⁵I放射性粒子植入术治疗肝恶性肿瘤的疗效分析[J]. 介入放射学杂志, 2020, 29(6): 587-590.
[43]	Eriguchi T, Takeda A, Sanuki N, et al. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system[J]. Int J Radiat Oncol Biol Phys, 2013, 85(4): 1006-1011.
[44]	Korean Liver Cancer Association (KLCA), National Cancer Center (NCC).2018 Korean liver cancer association-national cancer center korea practice guidelines for the management of hepatocellular carcinoma[J]. Korean J Radiol, 2019, 20(7): 1042-1113.
[45]	Zhou J, Sun H, Wang Z, et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)[J]. Liver Cancer, 2020, 9(6): 682-720.
[46]	Wong TC, Chiang CL, Lee AS, et al. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: a propensity score matched analysis[J]. Surg Oncol, 2019, 28: 228-235.
[47]	Rosenberg SA, Henke LE, Shaverdian N, et al. A multi-institutional experience of MR-guided liver stereotactic body radiation therapy[J]. Adv Radiat Oncol, 2019, 4(1): 142-149.
[48]	Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy for liver tumours: visualising the future[J]. Lancet Oncol, 2020, 21(2): e74-e82.
[49]	Llovet JM, Ricci S,Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
[50]	Thüring J, Zimmermann M, Bruners P, et al. Short-term oral sorafenib for therapy of intratumoral shunts of hepatocellular carcinoma to enable intraarterial treatment[J]. Cardiovasc Intervent Radiol, 2019, 42(10): 1494-1499.
[51]	曾云建, 毛颖民, 史自立, 等. 聚乙烯醇化疗栓塞联合阿帕替尼治疗晚期原发性肝癌合并动静脉分流的效果[J]. 介入放射学杂志, 2019, 28(10): 949-953.
[52]	Huang Y, Liu C, Zeng WC, et al. Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway[J]. Biosci Rep, 2020, 40(1): BSR20192727.
[53]	Yuan Q, Yao F, Zhou L, et al. Yu Ping Feng San exert anti-angiogenesis effects through the inhibition of TSLP-STAT3 signaling pathways in hepatocellular carcinoma[J]. Evid Based Complement Alternat Med, 2019, 2019: 1947156.
[54]	Su Q, Fan M, Wang J, et al. Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma[J]. Cell Death Dis, 2019, 10(12): 939.
[55]	Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699.
[56]	Mazzaferro V, Bhoori S,Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience[J]. Liver Transpl, 2011, 17 Suppl 2: S44-57.
[57]	夏永祥, 张峰, 李相成, 等. 原发性肝癌10 966例外科治疗分析[J]. 中华外科杂志, 2021, 59(1): 6-17.

Please choose a citation manager

Content to export